Drug news
UK NICE rejects Daxas (roflumilast) for chronic obstructive pulmonary disease- AstraZeneca
The UK National Institute for Health and Care Excellence has rejected Daxas (roflumilast) from AstraZeneca, for use by the NHS to treat certain patients with chronic obstructive pulmonary disease (COPD). Draft guidelines do not recommend the drug as an add-on to bronchodilator treatment for severe forms of the disease in adults with chronic bronchitis and frequent exacerbations.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.